EF Hutton analyst Elemer Piros reiterates GH Research (NASDAQ:GHRS) with a Buy and maintains $33 price target.
Baird Maintains Outperform on Twist Bioscience, Lowers Price Target to $33
Baird analyst Catherine Schulte maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and lowers the price target from $56 to $33.